{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/prescribing-information/mirtazapine/","result":{"pageContext":{"chapter":{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine","depth":2,"htmlHeader":"<!-- begin field 56ef89c7-92cf-4ec5-88cd-ab1a00fb62c3 --><h2>Mirtazapine</h2><!-- end field 56ef89c7-92cf-4ec5-88cd-ab1a00fb62c3 -->","summary":"","htmlStringContent":"<!-- begin item 98fe3e89-79ef-42a4-933a-ab1a00fb6299 --><!-- end item 98fe3e89-79ef-42a4-933a-ab1a00fb6299 -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"aa861802-aa76-59c1-88ca-1f0a7ff96c99","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5c8271fa-d2f1-4673-af21-ab1a00fc73ac --><h3>Contraindications and cautions</h3><!-- end field 5c8271fa-d2f1-4673-af21-ab1a00fc73ac -->","summary":"","htmlStringContent":"<!-- begin item d3191232-c73d-4b7a-b3f1-ab1a00fc737d --><!-- begin field fc51477d-4264-4dcc-b82f-ab1a00fc73ac --><ul><li><strong>Do not prescribe mirtazapine to people:</strong><ul><li>Aged under 18 years.</li></ul></li><li><strong>Prescribe mirtazapine with caution in the elderly and people with:</strong><ul><li>Cardiac disorders.</li><li>Diabetes mellitus.</li><li>Hepatic impairment.</li><li>Hypotension.</li><li>History of bipolar depression.</li><li>History of seizures.</li><li>History of urinary retention</li><li>Psychosis.</li><li>Renal impairment</li><li>Susceptibility to closed-angle glaucoma.</li><li>Susceptibility to hyponatraemia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field fc51477d-4264-4dcc-b82f-ab1a00fc73ac --><!-- end item d3191232-c73d-4b7a-b3f1-ab1a00fc737d -->","subChapters":[]},{"id":"21774fbd-bdd6-5402-9e28-f70f25624786","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 7fa4475a-3f6d-4fc5-9af3-ab1a00fc7ee8 --><h3>Adverse effects</h3><!-- end field 7fa4475a-3f6d-4fc5-9af3-ab1a00fc7ee8 -->","summary":"","htmlStringContent":"<!-- begin item 19b15be5-df8e-417b-ac85-ab1a00fc7e74 --><!-- begin field 3853247e-947b-4f11-af4b-ab1a00fc7ee8 --><ul><li><strong>Gastrointestinal</strong> — dry mouth (very common); nausea, vomiting, diarrhoea, constipation (common).<ul><li><strong>Rarely</strong>: pancreatitis.</li></ul></li><li><strong>Nervous system </strong>— somnolence, sedation, headache (very common); lethargy, dizziness, tremor (common); paraesthesia, restless legs, syncope (uncommon).<ul><li><strong>Rarely</strong>: myoclonus.</li><li><strong>Frequency unknown</strong>: serotonin syndrome, convulsions.</li></ul></li><li><strong>Psychiatric </strong>— abnormal dreams, confusion, anxiety, insomnia (common); nightmares, agitation, hallucinations, mania (uncommon).<ul><li><strong>Rarely</strong>: aggression.</li><li><strong>Unknown frequency</strong>: suicidal thoughts and behaviour.</li></ul></li><li><strong>Skin and subcutaneous tissue </strong>— exanthema (common).<ul><li><strong>Frequency unknown</strong>: Stevens-Johnson syndrome, dermatitis bullous, erythema multiforme, toxic epidermal necrolysis.</li></ul></li><li>Other adverse effects include:<ul><li>Appetite and weight increases.</li><li>Arthralgia, myalgia.</li><li>Blood dyscrasias.</li><li>Fatigue.</li><li>Hyponatraemia.</li><li>Liver enzyme increases.</li><li>Oedema.</li><li>QT interval prolongation.</li><li>Urinary retention.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 3853247e-947b-4f11-af4b-ab1a00fc7ee8 --><!-- end item 19b15be5-df8e-417b-ac85-ab1a00fc7e74 -->","subChapters":[]},{"id":"2f0d65ec-e145-5aa3-9233-cd82f84da95a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d0ffe261-45dc-4a4e-8cba-ab1a00fc8b68 --><h3>Drug interactions</h3><!-- end field d0ffe261-45dc-4a4e-8cba-ab1a00fc8b68 -->","summary":"","htmlStringContent":"<!-- begin item 465d3621-1ccd-4c68-9acb-ab1a00fc8b3b --><!-- begin field af110962-b9c9-4e0a-b36a-ab1a00fc8b68 --><ul><li><strong>Antiepileptics</strong> — mirtazapine can reduce the seizure threshold, and carbamazepine, phenobarbital and phenytoin decrease mirtazapine levels.</li><li><strong>Chlorpromazine </strong>— increased risk of agranulocytosis. Monitor for blood dyscrasias.</li><li><strong>Monoamine oxidase inhibitors</strong> (MAOIs) — increased risk of developing serotonin syndrome. Avoid concurrent use (and for 2 weeks after stopping either drug).</li><li><strong>Rifampicin</strong> — decreases levels of mirtazapine. Dose adjustments may be necessary.</li><li><strong>Other sedative drugs (alcohol, barbiturates, benzodiazepines)</strong> — mirtazapine is sedating and co-administration with other sedating drugs may have a synergistic effect.</li><li><strong>Drugs which may increase the risk of serotonin syndrome if taken concurrently with mirtazapine include:</strong><ul><li>Lithium.</li><li>Opioids — fentanyl, tramadol.</li><li>SNRIs — venlafaxine, duloxetine.</li><li>St John’s wort.</li><li>Tricyclic antidepressants — clomipramine, imipramine.</li><li>Triptans — sumatriptan, naratriptan.</li><li>Vortioxetine.</li></ul></li><li><strong>Drugs which may increase the levels of mirtazapine include:</strong><ul><li>Antifungals – itraconazole, ketoconazole, voriconazole.</li><li>Cimetidine.</li><li>Erythromycin.</li><li>HIV protease inhibitors — ritonavir, saquinavir.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">ABPI, 2018a</a>]</p><!-- end field af110962-b9c9-4e0a-b36a-ab1a00fc8b68 --><!-- end item 465d3621-1ccd-4c68-9acb-ab1a00fc8b3b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}